2022
Design and Basic Characteristics of a National Patient-Powered Registry in ADPKD
Hoover E, Perrone RD, Rusconi C, Benson B, Dahl NK, Gitomer B, Manelli A, Mrug M, Park M, Seliger SL, Phadnis MA, Thewarapperuma N, Watnick TJ. Design and Basic Characteristics of a National Patient-Powered Registry in ADPKD. Kidney360 2022, 3: 1350-1358. PMID: 36176661, PMCID: PMC9416821, DOI: 10.34067/kid.0002372022.Peer-Reviewed Original ResearchConceptsAutosomal dominant polycystic kidney diseaseKidney diseaseCore questionnaireManagement of ADPKDPatient-reported diagnosisPost-kidney transplantHealth-related qualityPatient-centered outcomesDominant polycystic kidney diseaseQuality of lifePolycystic kidney diseaseHispanics/LatinosCKD stageKidney transplantMedian ageKidney functionNational PatientBurden scoreDisease stageExtrarenal manifestationsPatient enrollmentADPKD patientsCreatinine valuesClinical trialsClinical studies
2020
A Time-Updated, Parsimonious Model to Predict AKI in Hospitalized Children
Sandokji I, Yamamoto Y, Biswas A, Arora T, Ugwuowo U, Simonov M, Saran I, Martin M, Testani JM, Mansour S, Moledina DG, Greenberg JH, Wilson FP. A Time-Updated, Parsimonious Model to Predict AKI in Hospitalized Children. Journal Of The American Society Of Nephrology 2020, 31: 1348-1357. PMID: 32381598, PMCID: PMC7269342, DOI: 10.1681/asn.2019070745.Peer-Reviewed Original ResearchConceptsExternal validation cohortValidation cohortElectronic health recordsSevere AKIClinical risk stratification toolDevelopment of AKIHealth recordsRisk stratification toolInternal validation cohortLength of stayCharacteristic curveElectronic medical recordsNeonatal AKIInpatient mortalitySecondary outcomesHospital admissionPrimary outcomeHospitalized childrenCreatinine valuesMedical recordsStudy populationAKICohortChildrenPredictive variables
2015
False-Positive Rate of AKI Using Consensus Creatinine–Based Criteria
Lin J, Fernandez H, Shashaty MG, Negoianu D, Testani JM, Berns JS, Parikh CR, Wilson FP. False-Positive Rate of AKI Using Consensus Creatinine–Based Criteria. Clinical Journal Of The American Society Of Nephrology 2015, 10: 1723-1731. PMID: 26336912, PMCID: PMC4594067, DOI: 10.2215/cjn.02430315.Peer-Reviewed Original ResearchConceptsSerum creatinine valuesGlobal Outcomes creatinine criteriaSerum creatinineCreatinine valuesCreatinine criteriaClinical cohortBiologic variabilityProportion of patientsSerum creatinine changesHigher baseline valuesFalse positive rateAKI diagnosisAKI studiesAdult patientsCreatinine changesBlood drawReference cohortOverall false-positive rateBaseline valuesCreatinine measurementsPatientsCreatinineHypothetical patientsDiagnosis rateSimulation cohortAutomated, electronic alerts for acute kidney injury: a single-blind, parallel-group, randomised controlled trial
Wilson FP, Shashaty M, Testani J, Aqeel I, Borovskiy Y, Ellenberg SS, Feldman HI, Fernandez H, Gitelman Y, Lin J, Negoianu D, Parikh CR, Reese PP, Urbani R, Fuchs B. Automated, electronic alerts for acute kidney injury: a single-blind, parallel-group, randomised controlled trial. The Lancet 2015, 385: 1966-1974. PMID: 25726515, PMCID: PMC4475457, DOI: 10.1016/s0140-6736(15)60266-5.Peer-Reviewed Original ResearchConceptsAcute kidney injuryUsual care groupKidney injuryCare groupAlert groupClinical outcomesElectronic alertsEligible participantsKidney Disease Improving Global OutcomesEnd-stage renal diseaseAcute kidney injury alertsEffective treatment optionIntensive care unitElectronic alert systemComputer-generated sequenceRandomisation strataSurgical admissionsUsual carePrimary outcomeRenal diseaseCare unitTreatment optionsCreatinine valuesCreatinine concentrationSuch injuries
2014
Steviol retards renal cyst growth through reduction of CFTR expression and inhibition of epithelial cell proliferation in a mouse model of polycystic kidney disease
Yuajit C, Muanprasat C, Gallagher AR, Fedeles SV, Kittayaruksakul S, Homvisasevongsa S, Somlo S, Chatsudthipong V. Steviol retards renal cyst growth through reduction of CFTR expression and inhibition of epithelial cell proliferation in a mouse model of polycystic kidney disease. Biochemical Pharmacology 2014, 88: 412-421. PMID: 24518257, DOI: 10.1016/j.bcp.2014.01.038.Peer-Reviewed Original ResearchConceptsAutosomal dominant polycystic kidney diseasePolycystic kidney diseaseRenal cyst growthCyst-lining epithelial cellsMouse modelKidney diseaseEpithelial cell proliferationEffect of steviolCyst enlargementCyst growthCell proliferationEpithelial cellsBlood urea nitrogenHuman autosomal dominant polycystic kidney diseaseDominant polycystic kidney diseaseOrthologous mouse modelChloride channel expressionRenal epithelial cell proliferationTransepithelial fluid secretionADPKD mouse modelRenal failureKidney functionKidney weightDaily treatmentCreatinine values
2010
Characteristics of Patients With Improvement or Worsening in Renal Function During Treatment of Acute Decompensated Heart Failure
Testani JM, McCauley BD, Kimmel SE, Shannon RP. Characteristics of Patients With Improvement or Worsening in Renal Function During Treatment of Acute Decompensated Heart Failure. The American Journal Of Cardiology 2010, 106: 1763-1769. PMID: 21055713, PMCID: PMC2997119, DOI: 10.1016/j.amjcard.2010.07.050.Peer-Reviewed Original ResearchMeSH KeywordsAcute DiseaseCardiotonic AgentsCatheterization, Swan-GanzCreatinineDisease ProgressionFemaleFollow-Up StudiesGlomerular Filtration RateHeart FailureHumansInfusions, IntravenousMaleMiddle AgedPrognosisPulmonary Wedge PressureRecovery of FunctionRenal InsufficiencyRetrospective StudiesStroke VolumeVasodilator AgentsConceptsDecompensated heart failureRenal functionStable renal functionCardiac indexHeart failureVasodilator usePulmonary Artery Catheterization Effectiveness trialAcute decompensated heart failureSimilar hemodynamic parametersCharacteristics of patientsCongestive heart failureComparison of patientsAdvanced disease stateCardiorenal interactionsIntravenous inotropesCause mortalityWorse survivalHemodynamic variablesPoor prognosisCreatinine valuesEffectiveness trialHemodynamic parametersHemodynamic differencesPatientsDisease states
2002
Evolving role of sirolimus immunosuppression after organ transplantation
Formica R, Friedman A, Lorber M. Evolving role of sirolimus immunosuppression after organ transplantation. Current Opinion In Organ Transplantation 2002, 7: 353-358. DOI: 10.1097/00075200-200212000-00009.Peer-Reviewed Original ResearchCalcineurin inhibitorsOrgan transplantationG1-S phase cell cycle arrestHigher serum creatinine valuesBiologic side effectsSirolimus-treated patientsCalcineurin inhibitor tacrolimusSerum creatinine valuesPivotal clinical trialsReduced rejection ratesPhase cell cycle arrestAllograft arteriosclerosisSirolimus immunosuppressionTriglyceride elevationLymphocele formationSirolimus useReversible thrombocytopeniaSerum cholesterolCreatinine valuesCell cycle arrestClinical trialsSide effectsSirolimusComplex woundsFull dose
1992
A THREE-YEAR EXPERIENCE WITH SERUM ANODAL TRYPSINOGEN AS A BIOCHEMICAL MARKER FOR REJECTION IN PANCREATIC ALLOGRAFTS
PERKAL M, MARKS C, LORBER M, MARKS W. A THREE-YEAR EXPERIENCE WITH SERUM ANODAL TRYPSINOGEN AS A BIOCHEMICAL MARKER FOR REJECTION IN PANCREATIC ALLOGRAFTS. Transplantation 1992, 53: 415-419. PMID: 1371196, DOI: 10.1097/00007890-199202010-00028.Peer-Reviewed Original ResearchConceptsPancreatic allograftsSPK recipientsAcute rejectionBiochemical markersWhole organ pancreas transplantationClinical diagnosisPrevious kidney transplantSerial serum samplesType I diabeticsThree-year experienceAllograft survivalGraft biopsyGraft duodenumPancreatic rejectionGraft pancreatitisPancreas transplantationKidney transplantOutlet obstructionSerum creatinineAdditional patientsImmunosuppressive agentsDirect traumaPresumptive diagnosisCreatinine valuesAmylase output
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply